[Intermediate doses of cytosine arabinoside in the treatment of acute non-lymphoblastic leukaemia in children].
Between 1995-1997, at 7 centres of the Polish Paediatric Leukaemia/Lymphoma Study Group (PPLLSG) treatment was started in 102 children with acute non-lymphoblastic leukaemia. Sixty-two children treated according to the new protocol adjusted for risk factors were evaluated. Thirty-one patients belonged to standard risk and 23 to high risk group. Eight children were not evaluated due to early death. Out of 62 children, 44 (70,9%) achieved remission; in standard and high risk groups the rates of remission were 87,5% and 73%, respectively. Four-year event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS) probability in all patients were: 40,2%, 42% and 59% respectively, in standard risk group: 49,5%, 52,5%, 59,1%; in high risk group: 42%, 43,4% and 57,8%. In comparison with the previous period (1983-1994) EFS increased from 30% to 42%, which was statistically insignificant.
Dluzniewska
A
A
Klinika Onkologii i Hematologii Dzieciecej, PA Instytut Pediatrii, Wydziału Lekarski UJ, 30-663 Krakow, ul. Wielicka 265, Poland.
Balwierz
W
W
Moryl-Bujakowska
A
A
Bogusławska-Jaworska
J
J
Dobaczewski
G
G
Januszkiewicz-Lewandowska
D
D
Kołecki
P
P
Kowalczyk
J
J
Krenke
K
K
Matysiak
M
M
Rokicka-Milewska
R
R
Rola-Kurc
E
E
Sońta-Jakimczyk
D
D
Stefaniak
M J
MJ
Tomaszewska
R
R
D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage*; D003630:Daunorubicin / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D011044:Poland / Q000453:epidemiology; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin